Aardvark Therapeutics Inc (AARD)

Dec 15, 2025

Insider Buying: Aardvark Therapeutics CEO, Secretary & Director Bought US$101k Of Shares - simplywall.st

Dec 15, 2025

Dec 15, 2025

HC Wainwright Has Negative Outlook for AARD FY2025 Earnings - Defense World

Dec 15, 2025

Dec 13, 2025

Aardvark Therapeutics (NASDAQ:AARD) CEO Tien-Li Lee Purchases 7,000 Shares - MarketBeat

Dec 13, 2025

Dec 13, 2025

Aardvark Therapeutics (NASDAQ:AARD) CFO Purchases $43,200.00 in Stock - MarketBeat

Dec 13, 2025

Dec 13, 2025

Insider Stock Purchases: December 13, 2025 - Quiver Quantitative

Dec 13, 2025

Dec 13, 2025

William Blair initiates coverage on Aardvark Therapeutics stock with Outperform rating - Investing.com Canada

Dec 13, 2025

Dec 12, 2025

Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 By Investing.com - Investing.com Nigeria

Dec 12, 2025

Dec 12, 2025

Insider Buying: Nelson Sun Acquires Additional Shares of Aardvar - GuruFocus

Dec 12, 2025

Dec 12, 2025

Lee Tien-Li, CEO of Aardvark, buys $101k in AARD stock - Investing.com Australia

Dec 12, 2025

Dec 12, 2025

Sun Nelson, CFO, buys Aardvark Therapeutics shares worth $43,200 - Investing.com

Dec 12, 2025

Dec 12, 2025

William Blair Initiates Coverage of Aardvark Therapeutics (AARD) with Outperform Recommendation - Nasdaq

Dec 12, 2025

Dec 12, 2025

Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst - Benzinga

Dec 12, 2025

Dec 12, 2025

William Blair Initiates Aardvark Therapeutics With Outperform Rating - marketscreener.com

Dec 12, 2025

Dec 12, 2025

Aardvark Therapeutics: Innovative Therapies for PWS and Obesity with Significant Market Potential - TipRanks

Dec 12, 2025

Dec 11, 2025

Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy By Investing.com - Investing.com South Africa

Dec 11, 2025

Dec 11, 2025

Aardvark Therapeutics’ Promising Progress and Market Potential: Analyst Recommends Buy - TipRanks

Dec 11, 2025

Dec 11, 2025

Aardvark Therapeutics stock rises 13% on positive trial updates, BTIG maintains Buy - Investing.com Canada

Dec 11, 2025

Dec 11, 2025

Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target - Investing.com Nigeria

Dec 11, 2025

Dec 11, 2025

Raymond James reiterates Strong Buy on Aardvark Therapeutics stock with $47 target By Investing.com - Investing.com South Africa

Dec 11, 2025

Dec 11, 2025

Aardvark doses first Australian patient in phase 3 PWS hunger trial - Investing.com Nigeria

Dec 11, 2025

Dec 10, 2025

Aardvark doses first Australian patient in phase 3 PWS hunger trial By Investing.com - Investing.com South Africa

Dec 10, 2025

Dec 10, 2025

Aardvark Therapeutics Begins Phase 3 HERO Trial Dosing - TipRanks

Dec 10, 2025

Dec 10, 2025

Aardvark Therapeutics Doses First Patient in HERO Phase 3 Trial - TradingView — Track All Markets

Dec 10, 2025

Dec 10, 2025

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome - The Manila Times

Dec 10, 2025

Dec 10, 2025

Aardvark Therapeutics (Nasdaq: AARD) expands HERO PWS trial, targets Q3 2026 data - Stock Titan

Dec 10, 2025

Dec 10, 2025

Aardvark Therapeutics begins phase 3 HERO trial dosing - MSN

Dec 10, 2025

Dec 05, 2025

Retail Investors in Aardvark Therapeutics, Inc. (NASDAQ:AARD) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 28% Last Week - 富途牛牛

Dec 05, 2025

Dec 05, 2025

Will Aardvark Therapeutics Inc. stock benefit from commodity pricesMarket Growth Report & Daily Market Momentum Tracking - Newser

Dec 05, 2025

Dec 04, 2025

Aardvark Therapeutics up 9% at $10.10 after Raymond James Strong Buy initiation - MSN

Dec 04, 2025

Dec 04, 2025

Raymond James Financial Begins Coverage on Aardvark Therapeutics (NASDAQ:AARD) - MarketBeat

Dec 04, 2025

Dec 04, 2025

Individual investors among Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) largest shareholders, saw gain in holdings value after stock jumped 23% last week - simplywall.st

Dec 04, 2025

Dec 03, 2025

Aardvark Therapeutics initiated with a Strong Buy at Raymond James - MSN

Dec 03, 2025

Dec 03, 2025

AARD: Phase 3 Prader-Willi data expected Q3 2026; obesity program readout by end of next year - TradingView

Dec 03, 2025

Dec 03, 2025

Aardvark Therapeutics (AARD) Stock Analysis Report | Financials & Insights - Benzinga

Dec 03, 2025

Dec 03, 2025

Raymond James Initiates Aardvark Therapeutics at Strong Buy - marketscreener.com

Dec 03, 2025

Dec 02, 2025

Raymond James initiates coverage on Aardvark Therapeutics stock with Strong Buy - Investing.com UK

Dec 02, 2025

Dec 02, 2025

AARDAardvark Therapeutics Inc Dividends - Finviz

Dec 02, 2025

Dec 01, 2025

Aardvark Therapeutics Reports Q3 2025 Financial Results - MSN

Dec 01, 2025

Nov 30, 2025

Aardvark Therapeutics Hosts Investor Webinar on Drug Programs - MSN

Nov 30, 2025

Nov 30, 2025

Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) PT at $30.63 - Defense World

Nov 30, 2025

Nov 28, 2025

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Nov 28, 2025

Nov 26, 2025

What risks investors should watch in Aardvark Therapeutics Inc. stockEarnings Trend Report & Real-Time Chart Breakout Alerts - BỘ NỘI VỤ

Nov 26, 2025

Nov 26, 2025

Aardvark Therapeutics to Present at Upcoming Investor Conferences in December - The Manila Times

Nov 26, 2025

Nov 25, 2025

What is the current Price Target and Forecast for Aardvark Therapeutics, Inc. (AARD) - Zacks Investment Research

Nov 25, 2025